Sanuwave Health (SNWV) to Release Quarterly Earnings on Friday

Key Points

• Sanuwave Health is expected to report Q2 2026 results with analysts forecasting a loss of $0.03 per share and revenue of $11.50 million.
• The company’s most recent quarter fell short of expectations, reporting an $0.08-per-share loss and $9.74 million in revenue versus the $11.50 million consensus estimate.
• SNWV shares opened at $6.00, near their 52-week low of $5.77. Analysts collectively rate the stock “Moderate Buy,” with an average price target of $51, while institutional investors own 42.53% of outstanding shares.

Sanuwave Health (NASDAQ:SNWV - Get Free Report) is projected to release its Q2 2026 results before the market opens on Friday, August 14th. Analysts expect the company to announce earnings of ($0.03) per share and revenue of $11.50 million for the quarter. Investors can check the company's upcoming Q2 2026 earning results page for the latest details on the call scheduled for Friday, August 7, 2026 at 8:30 AM ET.

Sanuwave Health (NASDAQ:SNWV - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.03) by ($0.05). Sanuwave Health had a net margin of 35.96% and a negative return on equity of 450.56%. The firm had revenue of $9.74 million during the quarter, compared to analyst estimates of $11.50 million.

Sanuwave Health Trading Up 0.5%

Shares of SNWV stock opened at $6.00 on Friday. The stock has a 50-day simple moving average of $9.91 and a 200 day simple moving average of $17.08. The stock has a market capitalization of $51.60 million, a P/E ratio of 18.18 and a beta of 1.48. Sanuwave Health has a fifty-two week low of $5.77 and a fifty-two week high of $46.58. The company has a quick ratio of 0.99, a current ratio of 1.31 and a debt-to-equity ratio of 8.15.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a "hold (c-)" rating on shares of Sanuwave Health in a report on Wednesday, June 24th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $51.00.

Institutional Investors Weigh In On Sanuwave Health

A number of institutional investors and hedge funds have recently modified their holdings of SNWV. Praetorian PR LLC raised its position in shares of Sanuwave Health by 1,436.2% during the fourth quarter. Praetorian PR LLC now owns 265,000 shares of the company's stock worth $7,908,000 after purchasing an additional 247,750 shares during the period. Stifel Financial Corp purchased a new stake in shares of Sanuwave Health during the fourth quarter valued at $5,291,000. Geode Capital Management LLC acquired a new position in shares of Sanuwave Health in the 2nd quarter valued at $5,184,000. Lazard Asset Management LLC acquired a new position in shares of Sanuwave Health in the 2nd quarter valued at $738,000. Finally, Jane Street Group LLC purchased a new position in Sanuwave Health in the 4th quarter worth about $587,000. Institutional investors and hedge funds own 42.53% of the company's stock.

Sanuwave Health Company Profile

Sanuwave Health, Inc is a medical technology company specializing in the development and commercialization of non-invasive acoustic wave therapies designed to stimulate tissue regeneration and accelerate healing. The company's proprietary Extracorporeal Pulse Activated Technology (EPAT) delivers focused acoustic pressure waves to injured or chronic wound sites, activating the body's natural repair mechanisms. Sanuwave's primary therapeutic areas include advanced wound care for diabetic and venous ulcers, as well as orthopedic and musculoskeletal conditions.

The company's lead product, the dermaPACE® system, holds clearance from the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source